# US 2023/0406842 A1 · Small molecule compound serving as jak kinase inhibitor, and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0406842 A1
- Document ID: US20230406842A1
- Status: Published application
- Kind: A1
- Application number: 18/030,962
- Filed: 2021-09-24
- Published: 2023-12-21
- Earliest claimed: 2020-10-09
- Assignees: Technoderma Medicines, Inc.
- Applicants: Technoderma Medicines, Inc.
- Inventors: Wenkui Ken FANG; Guanqun LI; Yuting CAI; Xiang PAN; Wenhao ZHU; Yang WANG; Zengquan WANG
- Web page: https://patentgrep.com/patent/US20230406842A1

## CPC

- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- C07D 403/14: containing three or more hetero rings
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/06: Antipsoriatics
- A61P 17/10: Anti-acne agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C07D 401/14: containing three or more hetero rings
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The present invention provides a small molecule compound. The small molecule compound is a compound represented by the following formula (I), or a stereoisomer, geometric isomer, tautomer, hydrate, solvate, and pharmaceutically acceptable salt or prodrug thereof, wherein R1 to R5 are each independently selected from C or N; and R is selected from cycloalkyl, substituted cycloalkyl, heterocycloalkyl, substituted heterocycloalkyl, aryl, substituted aryl, heteroaryl, or substituted heteroaryl. The small molecule compound of the present invention can inhibit the JAK kinase, and is particularly used as a JAK1/Tyk2 dual inhibitor and a Tyk2 specific inhibitor.

## Claims

### Claim 1

A small molecule compound, wherein the small molecule compound is a compound represented by Formula I, or a stereoisomer, a geometric isomer, a tautomer, a hydrate, a solvate, a pharmaceutically acceptable salt or a prodrug thereof:
wherein R1 to R5 are each independently selected from C or N; and
wherein R is selected from a cycloalkyl group, a substituted cycloalkyl group, a heterocycloalkyl group, a substituted heterocycloalkyl group, an aryl group, a substituted aryl group, a heteroaryl group, or a substituted heteroaryl group.

### Claim 2 (depends on 1)

The small molecule compound according to claim 1, wherein at most two of R1 to R5 are N.

### Claim 3 (depends on 1)

The small molecule compound according to claim 1, wherein R has a structure represented by Formula II below:
wherein R5 is selected from C or N;
wherein R7 is selected from hydrogen, halogen, an alkyl group, an amino group, an amido group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, or a heteroaryl group; and
wherein R5 is selected from hydrogen, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, or a heteroaryl group.

### Claim 4 (depends on 3)

The small molecule compound according to claim 3, wherein R7 and R8 are each independently selected from hydrogen, an alkyl group, or a cycloalkyl group.

### Claim 5 (depends on 1)

The small molecule compound according to claim 1, wherein R has a structure represented by Formula III:
wherein R9 is selected from C or N;
wherein R10 is selected from hydrogen, halogen, an alkyl group, an amino group, an amido group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, or a heteroaryl group; and
wherein R11 is selected from hydrogen, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, or a heteroaryl group.

### Claim 6 (depends on 5)

The small molecule compound according to claim 5, wherein R10 and R1 are each independently selected from hydrogen, an alkyl group, or a cycloalkyl group.

### Claim 7 (depends on 4)

The small molecule compound according to claim 4, wherein the alkyl group is a methyl group, an ethyl group, a propyl group, or an isopropyl group, and the cycloalkyl group is a cyclopropyl group, a cyclobutyl group, or a cyclopropylmethyl group.

### Claim 8 (depends on 1)

A method for inhibition of JAK kinase using small molecule compound according to claim 1.

### Claim 9 (depends on 1)

A method for prevention or treatment of an autoimmune disease and an immune-related inflammatory skin disease using the small molecule compound according to claim 1, wherein pathogenesis of each of the diseases is associated with a disorder in JAK signaling.

### Claim 10 (depends on 9)

The method according to claim 9, wherein the autoimmune disease is at least one selected from the group consisting of rheumatoid arthritis, ankylosing spondylitis, ulcerative colitis, Crohn's disease, systemic lupus erythematosus, dermatomyositis, multiple sclerosis, type I diabetes mellitus, Sjogren's syndrome, and vasculitis.

### Claim 11 (depends on 9)

The method according to claim 9, wherein the immune-related inflammatory skin disease is at least one selected from the group consisting of atopic dermatitis, eczema, alopecia areata, psoriasis, vitiligo, lichen planus, lichen nitidus, lichen sclerosus et atrophicus, panniculitis, acne, and hidradenitis suppurativa.

### Claim 12 (depends on 6)

The small molecule compound according to claim 6, wherein the alkyl group is a methyl group, an ethyl group, a propyl group, or an isopropyl group, and the cycloalkyl group is a cyclopropyl group, a cyclobutyl group, or a cyclopropylmethyl group.
